Haemophilia A

9
Pipeline Programs
4
Companies
20
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
5
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 19 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
17 programs
4
5
Mim8Phase 31 trial
NNC0365-3769Phase 31 trial
NNC0365-3769Phase 31 trial
Turoctocog alfaPhase 31 trial
turoctocog alfa pegolPhase 31 trial
+12 more programs
Active Trials
NCT06285071Enrolling By Invitation23Est. Apr 2030
NCT05621746Recruiting100Est. Jun 2026
NCT03741881Completed231Est. Oct 2021
+14 more trials
Swedish Orphan Biovitrum
2 programs
ELOCTAN/A1 trial
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With N/A1 trial
Active Trials
NCT03055611CompletedEst. Apr 2022
NCT03276130CompletedEst. Jan 2020
CSL Behring
CSL BehringIL - Bradley
1 program
Afstyla®N/A1 trial
Active Trials
NCT04675541Completed62Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Novo NordiskNNC0365-3769
Novo NordiskMim8
Novo NordiskNNC0365-3769
Novo Nordiskturoctocog alfa pegol
Novo NordiskTuroctocog alfa
Novo NordiskNNC0442-0344 A
Novo NordiskNNC0442-0344 A
Novo NordiskNNC0442-0344 A
Novo NordiskNNC0365-3769
Novo NordiskConcizumab
Novo NordiskEsperoct
Novo NordiskTuroctocog alfa
Novo NordiskTuroctocog alfa pegol
Novo NordiskTuroctocog alfa pegol
Novo NordiskTuroctocog alfa pegol

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 2,373 patients across 20 trials

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

Start: Jun 2023Est. completion: Jul 202461 patients
Phase 3Completed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)

Start: Feb 2023Est. completion: Jun 2028451 patients
Phase 3Active Not Recruiting

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

Start: Dec 2021Est. completion: Dec 2024281 patients
Phase 3Completed
NCT05082116Novo Nordiskturoctocog alfa pegol

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)

Start: Sep 2021Est. completion: Dec 202236 patients
Phase 3Completed

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

Start: Jun 2018Est. completion: Jun 20191 patients
Phase 3Terminated

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

Start: Nov 2025Est. completion: Apr 202680 patients
Phase 1Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Start: Oct 2025Est. completion: Dec 202620 patients
Phase 1Recruiting

A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men

Start: Sep 2024Est. completion: May 2026108 patients
Phase 1Recruiting

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

Start: Jan 2023Est. completion: Oct 2023205 patients
Phase 1Completed

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Start: Aug 2024Est. completion: Apr 203023 patients
N/AEnrolling By Invitation

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Start: Nov 2022Est. completion: Jun 2026100 patients
N/ARecruiting

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

Start: Apr 2021Est. completion: Mar 202318 patients
N/ACompleted
NCT04334057Novo NordiskTuroctocog alfa pegol

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Start: Mar 2021Est. completion: Jan 202423 patients
N/ACompleted
NCT04682145Novo NordiskTuroctocog alfa pegol

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Start: Dec 2020Est. completion: Feb 202650 patients
N/AEnrolling By Invitation
NCT04574076Novo NordiskTuroctocog alfa pegol

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

Start: Oct 2020Est. completion: Jun 202760 patients
N/AEnrolling By Invitation
NCT03741881Novo NordiskNo treatment given

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)

Start: Dec 2018Est. completion: Oct 2021231 patients
N/ACompleted
NCT03276130Swedish Orphan BiovitrumManagement of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B

Start: Oct 2018Est. completion: Jan 2020
N/ACompleted
NCT03660774Novo NordiskNo treatment given

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

Start: Sep 2018Est. completion: Oct 2019563 patients
N/ACompleted

Register of Patients With haEmophilia A tReated With Afstyla®

Start: Sep 2018Est. completion: Dec 202462 patients
N/ACompleted

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Start: May 2017Est. completion: Apr 2022
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 2,373 patients
4 companies competing in this space